Immunome Inc
NASDAQ:IMNM
Immunome Inc
NASDAQ:IMNM
Price:
14.49 USD
-1.36%
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
IMNM
stock under the Base Case scenario is
1.3
USD.
Compared to the current market price of 14.49 USD,
Immunome Inc
is
Overvalued by 91%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IMNM
Relative Value
Base Case
1.3
USD
Overvaluation 91%
Valuation Multiples
Multiples Across Competitors
IMNM Competitors Multiples
Immunome Inc Competitors
Immunome Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Immunome Inc
NASDAQ:IMNM
|
876.9m USD | 61.7 | -8.1 | -26.1 | -25.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281B USD | 5.2 | 58.6 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.2B USD | 10.5 | 28.6 | 22.8 | 23.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
100.4B USD | 7.6 | 25.4 | 16.9 | 18.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.3B USD | 3 | 168.2 | 6.8 | 8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.6B USD | 6.6 | -9.6 | -10.4 | -8.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.3 | 26.8 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
